Ensifentrine nebulizer trial to reduce COPD airway inflammation markers
Part of Lungs & breathing clinical trials.
This trial tests ensifentrine, given through a nebulizer, to see if it changes inflammation-related substances found in mucus/phlegm in people with COPD. It may help doctors understand whether this treatment improves COPD biology and could lead to better symptom control.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re age 40 to 80 and have COPD confirmed by breathing test results and doctor history.
- You have a smoking history of at least 10 pack-years (pack-years = packs per day times years).
- Your lung function test (FEV1/FVC) is below 0.70 even after using albuterol/salbutamol, and your FEV1 after albuterol is between 30% and 80% of predicted.
- You’ve used a COPD “breathing controller” medicine regularly for at least 4 weeks, and you agree to keep using the trial’s once-daily maintenance therapy.
- You can use a jet nebulizer correctly, do spirometry (breathing tests), and provide sputum (mucus/phlegm) samples during the study procedure.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new inhaled medication, HRS-9821, in healthy people and in people with COPD. For COPD patients, the goal is to see how safe and well-tolerated multiple doses are, which could lead to a new treatment option.
This is an early-stage study testing a new inhaled medication (HRS-9821) to see if it is safe and how the body processes it. Researchers will first test it in healthy volunteers, then in people with COPD (chronic lung disease) to understand if it might help with breathing.
This study tests whether a new approach can help relieve severe shortness of breath in people with COPD who are already on standard inhaler therapy. It may help you breathe easier and improve your daily life.
This trial tests a new implant for people with severe emphysema. It aims to see if the implant can help you breathe easier and walk farther.
This trial tests an inhaled drug called ensifentrine in people with bronchiectasis (damaged, widened airways in the lungs). The goal is to see if it can reduce flare-ups and improve symptoms.
This trial tests a new medicine called PF-07275315 for people with moderate to severe COPD. It aims to see if it can help reduce flare-ups (sudden worsening of symptoms) when added to your usual treatment.
Hear when a new COPD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.